The Effect Of Lisinopril On Polycythemia
NCT07594535
This study is recruiting at 2 US sites in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to evaluate the effect of the (angiotensin-converting enzyme) ACE inhibitor lisinopril on hemoglobin, hematocrit, and erythropoietin levels in patients with secondary polycythemia due to high-oxygen-affinity hemoglobin variants, oxygen-sensing pathway mutations, or other unexplained and potentially irreversible forms of erythrocytosis. This study aims to determine whether ACE inhibition can effectively reduce excessive erythrocytosis by modulating erythropoietin production.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Polycythemia
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 4
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Mayo Clinic
- Last updated on ClinicalTrials.gov
- August 21, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Minnesota · 2
- Mayo Clinic · Rochester, MN
- St. Mary's Hospital · Rochester, MN
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.